Nanocrystal for Cancer Theranostics

For delivering poorly soluble anticancer agents, the current paradigm is to solubilize the drugs prior to the administration.  Our approach is to inject a drug as solid, crystalline particles of a few hundred nanometers without encapsulating and/or solubilizing chemicals and carriers.  Moreover, we have pioneered using hybrid nanocrystals to achieve concurrent chemotherapy and bioimaging.  The title picture shows some representative SEM images of paclitaxel and full-body images of mice that were treated by paclitaxel hybrid nanocrystals.

Our current efforts include (1) scale-up of nanocrystal production; (2) particle engineering of nanocrystals; and (3) in vivo tests of efficacy, toxicity, and theranostics.